164 - Strategic Approaches to Impurity Control in Multi-Step Organic Syntheses (S11E14)

Welcome to the Deep Dive. Today, we're tackling
a topic that's absolutely fundamental to the
medicines you rely on, impurities in drug development.
When scientists are creating new therapies, it's
not just about crafting the main active ingredient
perfectly. It's also about understanding and
controlling everything else that might be in
the mix. That's right. Those unintended components.
Exactly. They can impact how safe and effective
a drug is for you. Imagine you're building a
really complex machine. loads of tiny parts.
If even a few of those parts are slightly off,
or maybe there are unexpected little bits of
material left over from manufacturing, well,
it could affect how the whole thing works. Right,
it could even break down. Precisely. And in drug
development, these unexpected bits are the impurities.
So our deep dive today is all about where they
actually come from in the... intricate world
of organic synthesis. And it's not just about
playing detective, figuring out where they come
from, is it? No, not at all. It's also about
the sophisticated toolkit. The strategies used
to find them, keep tabs on them, and ultimately,
well, minimize or eliminate them. Absolutely.
We'll be exploring the analytical techniques
and the process controls that make this crucial
work possible. Because this isn't just like an
academic exercise. It has profound real -world
consequences for everyone. Definitely. Regulatory
agencies worldwide, like the FDA, they scrutinize
these impurities very closely. I bet. Their presence,
even in tiny, tiny amounts, can be a huge stumbling
block getting a new drug from the lab to, you
know, your medicine cabinet. So we're really
talking about safeguarding against potential
harm. Yes, and guaranteeing that each dose of
medication you get meets the highest standards
of consistent quality, batch to batch. Okay,
let's unpack this then. Where do these unwanted
guests, these impurities, actually sneak into
the process of making a drug? Sounds like there
could be multiple points of entry. Oh, indeed.
Given how complex organic synthesis often is,
multiple steps involved, there are several potential
sources. Like what? Well, one of the most common
is the starting materials. The initial building
blocks. Exactly. Think of them like that. If
these starting materials aren't highly pure to
begin with, then any impurities they contain
can unfortunately just carry through. Ah, so
they might appear in the final drug substance?
Potentially, yes. It's like trying to build a
perfect Lego castle with some bricks that are
already a bit chipped or off color. That makes
perfect sense. You can't really end up with a
pristine final product if you start with something
that's not quite right. Precisely. What other
factors can introduce impurities? The regions
we use. Yeah. The substances that actually drive
the chemical transformations. They're another
key source. Okay. These reagents themselves can
contain trace impurities or, interestingly, they
can even degrade under the conditions of the
reaction. Oh, really? So they break down. Yeah,
leading to the formation of new unwanted compounds.
And these chemical reactions, they can be quite
involved, right? Often a whole sequence of steps.
Exactly. Very carefully orchestrated sequences.
And during these steps, we form intermediates.
Right, temporary molecules. Molecules created
temporarily, then further transformed into the
final drug. Now, some of these intermediates...
they can be inherently unstable under the reaction
conditions. OK, so they might break down or react
in ways you didn't expect. Exactly. And this
can lead to impurity formation. We actually see
a clear example of this in one of our sources.
Oh, yeah. In a transition metal catalyzed coupling
reaction, an intermediate just wasn't stable
enough under the basic conditions used. And what
happened? Well, it led to a specific impurity.
known as Compound 16 and probably other larger
unwanted by -products too. We call those oligomerization
products. oligomerization. It's where intermediate
molecules start linking together forming bigger
unwanted chains. Gotcha. And what's really interesting
is that this issue became much, much worse when
they tried to scale up the reaction. Scale up,
you mean make larger quantities. Yes, to produce
larger batches of the drug. So what worked fine
when making a tiny amount in the lab became a
big problem when trying to manufacture it. Exactly.
That really highlights a critical point. What
works on a lab bench doesn't always translate
smoothly to large -scale production. Subtle changes
in conditions can dramatically impact impurity
formation, then. Precisely. There's another example
in our materials, too, about forming an isomeric
impurity compound 25. Isomeric. Same atoms, different
arrangement. That's right. And this happened
during the salt formation step. Again, it was
linked to slower processing times at larger scales.
So more time meant more opportunity for that
unwanted isomer to form. Seems like it. It shows
it's not just the ingredients but also the specific
conditions, the timing of the manufacturing process.
They all play a crucial role. Okay, so ingredients,
intermediates. What about the liquids? The stuff
the reactions happen in? Ah, solvents. Yes, another
potential contributor. Impurities already present
in the solvents themselves. Or even products
that form as the solvents degrade over time,
maybe under certain reaction conditions. they
could contaminate the reaction mixture. Makes
sense. And catalysts, the things that speed up
reactions. Yes, catalysts too. They're essential,
but they could also be sources of impurities.
How so? Either as trace amounts of the catalyst
itself just remaining in the product or from
the catalyst breaking down during the reaction.
Huh. It almost sounds like every single thing
we introduce into the synthesis has the potential
to bring along some unwanted baggage or create
new problems. That's a very astute way to put
it actually. That's a good observation. And then
of course even the reaction you want to happen.
It doesn't always go perfectly, right? Not always.
You can get reaction byproducts. Unintended side
products that form alongside your target drug
molecule. And examples of that. Yeah. Our sources
mentioned an unsuccessful attempt at a particular
reaction, a palladium catalyzed amino carbonylation.
Okay. Instead of mostly getting the desired amide
product, they ended up with significant amounts
of a ketone arylation product and an amination
product instead. So the reaction just took a
completely different path. Pretty much. leading
to these major unwanted molecules. It shows it's
not always a straight path to the drug we're
trying to make. There can be detours. Side roads
leading to impurities. Now this might seem obvious,
but what about the physical stuff, the equipment
used in manufacturing? That's an extremely important
point. Yes, the equipment and utensils. They
can introduce impurities. Absolutely. Think about
tiny amounts of lubricants from machinery, maybe
metal fragments, even residues from cleaning
agents if the equipment isn't cleaned perfectly.
Wow. And this is where regulations like CFR Title
21 Part 211 come in. Okay, regulations for the
hardware. Exactly. Part 211 is about the design
and maintenance of pharmaceutical manufacturing
equipment, specifically to prevent this kind
of adulteration, this contamination. And there
was another part mentioned. Part 111 also emphasizes
the critical need for clean and sanitary equipment,
and especially any surfaces that come into direct
contact with the drug substance. So it's not
just the chemistry inside the reaction vessel,
but the whole environment it's happening in.
Correct. The whole setup matters. Okay, so we
have all these potential sources of impurities,
starting materials, reagents, intermediates,
solvents, catalysts, byproducts, even the equipment.
How do scientists even know they're there? What's
the detective work involved? Ah, this is where
analytical chemistry becomes absolutely indispensable.
We rely on a whole suite of highly sophisticated
analytical techniques. To find and measure them.
Exactly. To detect and quantify these impurities,
which, you know, can often be present in incredibly
small amounts. So what are some of the key tools
in this analytical toolbox? Well, chromatography
techniques like HPLC, high -performance liquid
chromatography, and GC gas chromatography are
really the workhorses here. Chromatography. That
separates things out, right? That's the idea.
Imagine a race where different molecules move
at different speeds through some special material.
Chromatography separates the components of a
mixture based on these differences. So you can
see extra peaks in the results. Precisely. Keeks
besides the one you expect for your drug substance.
And often these chromatography techniques are
coupled with very sensitive detectors. Mass spectrometry,
MS, is a particularly powerful one. Mass spectrometry,
how does that help in this molecular detective
work? Mass spec essentially acts like a super
precise scale. It measures the mass to charge
ratio of individual molecules. Giving a unique
fingerprint. Pretty much, yeah. A unique fingerprint
for each component in the mixture. And advanced
mass spec techniques, like those using time of
flight or TOF, mass analyzers, offer exceptionally
high mass resolution. High resolution meaning?
Meaning much greater selectivity. We can distinguish
between molecules that have very, very similar
masses. Even tiny differences. Even tiny differences.
And even when we're looking at fragments of molecules
using something called tandem mass spectrometry,
or MSMS. Wow, that's like having a molecular
fingerprint. For real, it's incredible that we
can identify such minute differences. It really
is powerful stuff. And our sources also emphasize
the crucial importance of validation of these
analytical test procedures. Validation, meaning
proving the tests work. Exactly. Rigorously proving
that our tests are accurate, reliable, and sensitive
enough to detect and measure impurities at the
relevant levels. Okay. This includes determining
things like potential degradation products of
the drug and the lowest amount of impurity the
test can reliably detect. We call that the limit
of detection. Got it. So you need proof the methods
are up to the job. Absolutely. The Good Drug
Regulatory Practices source specifically highlights
these aspects. And I also noticed a mention of
NMR spectroscopy. How does that fit into the
puzzle? Ah, NMR spectroscopy, nuclear magnetic
resonance. It's a very powerful technique for
figuring out the detailed structure of molecules.
How they're put together? Exactly. While one
source mentions its use in structure activity
relationship studies, or SAR studies. Which is
about how structure affects biological activity.
Right. But its fundamental ability to map out
the precise arrangement of atoms makes it invaluable
for fully characterizing the structure of an
impurity once you've managed to separate and
isolate it using something like chromatography.
So chromatography finds it, mass spec fingerprints
it, and NMR maps its structure. That's a good
way to think about the workflow, yeah. Okay,
so once we've identified and characterized these
impurities, what steps can be taken to minimize
their formation in the first place? It can't
just be about finding them after they've formed,
right? No, prevention is key. We need to stop
them from happening. Precisely. This is where
implementing robust process controls is absolutely
essential. Process controls like? Well, a key
aspect is meticulously controlling the reaction
parameters. during the synthesis temperature
pressure exactly factors like temperature pressure
the duration of the reaction the reaction time
they can significantly influence impurity formation
so fine -tuning the recipe it's exactly like
fine -tuning a recipe yeah getting the temperature
and baking time just right to avoid you know
burning or undercooking. By carefully optimizing
these conditions, we can often minimize generating
unwanted byproducts. That's a great analogy.
Beyond just controlling the reaction itself,
what other strategies are used? Purification
techniques are critical at each step of the synthesis.
Like filtering things out. Methods like crystallization,
various forms of chromatography often done on
a much larger industrial scale and filtration,
yes. They're used to selectively remove impurities
that form during the previous reaction step.
So it's a cycle, react, then purify. Often, yes.
That example we discussed earlier needing extra
steps to remove that isomeric impurity compound
25 and improve the enantiomeric excess. The ratio
of the desired mirror image molecule. Right.
That really highlights the absolute necessity
of these purification steps. It's often a cycle.
reaction, purification, next reaction purification.
It sounds like a constant process of creating
and then cleaning up. It can be. And increasingly
the pharmaceutical industry is embracing a concept
called quality by design or QBD. Quality by design?
What's that about? It's a more systematic science
-based approach to drug development. It really
emphasizes deeply understanding the manufacturing
process. and identifying the critical parameters
that can impact the quality of the final drug,
including impurity levels. So designing the process
with quality in mind from the start. Exactly.
Instead of just relying on testing the quality
in at the end, by designing the process well,
we aim to minimize defects, including impurity
formation, right from the beginning. That sounds
much more proactive. It is. Several of our sources
mention QBD, including ones on process technology,
continuous manufacturing, and product development.
The insight is moving from testing quality in
to designing quality in. So instead of just testing
the final batch, you're engineering the whole
process to be inherently less likely to produce
impurities. That's the core idea. And it's closely
linked to the FDA's PAT framework process analytical
technology. Oh, I do. Yeah, PA encourages using
advanced process monitoring tools, tools that
measure critical quality attributes, which can
include indicators of impurity formation in real
time during manufacturing. Real time monitoring.
Yes, allowing for adjustments to be made proactively,
on the fly, to ensure consistent quality and
minimize variability, like having sensors and
feedback loops build right into the process.
Interesting. Are there specific guidelines the
industry follows for all this impurity control?
Oh yes, definitely. There are important regulatory
guidelines. The ICH Q11 guideline, for example.
ICH? International Council for Harmonization.
Q11 offers comprehensive guidance on developing
and manufacturing drug substances, with a big
focus on managing impurities throughout the whole
life cycle. And it mentions risk. Yes. It emphasizes
a risk -based reasoning for hazard assessment
of potential impurities. This is also highlighted
in the merged ICH Q914 document we look at. Risk
-based reasoning. So focusing on the impurities
that pose the greatest potential risk to patients.
Exactly right. Strategic. Prioritize identifying
and controlling the impurities most likely to
be present and most likely to cause harm if they
aren't properly controlled. This all sounds incredibly
intricate. and highly regulated. Why is having
this thorough understanding of impurity profiles
so absolutely critical for getting a drug approved
by the FDA, for instance? Well, ultimately it
comes down to ensuring patient safety. That's
the bottom line. Right. Regulatory agencies like
the FDA mandate a very comprehensive understanding
of the impurity profile of any new drug substance.
Meaning? Meaning not just identifying all potential
impurities you might reasonably expect. Okay.
But also precisely determining their levels in
the final drug product and then demonstrating
through rigorous testing and analysis that those
levels are within internationally accepted safety
limits. So it's not enough to just show the main
drug works and is safe. You have to prove everything
else present is also safe and acceptable. Absolutely.
And there's a particularly critical area of regulatory
concern. Genotoxic impurities. Genotoxic. Sounds
bad. It is. These are impurities that have the
potential to damage DNA and potentially cause
cancer. That's the concern. Yes. So regulatory
agencies have established very strict, often
extremely low, limits for these types of impurities.
Nukesense. Therefore, a deep understanding of
the chemical pathways, how potential genotoxins
might form during synthesis, is absolutely essential.
To develop control strategies. Exactly. Strategies
aimed at minimizing or completely eliminating
them. One of our sources specifically mentions
the ongoing concern around N -nitrosamines as
a class of hazardous substances. Nitrosamines,
right. I've heard about those. It really underscores
the intense regulatory focus on compounds like
that. Janotoxins. Definitely something you want
to keep out of medicines. What about when a company
is developing, say, a series of drug candidates
that are chemically similar? Like related structures?
Yeah. Does understanding the impurities in one
help with the others? Yes, absolutely. Understanding
the impurity profile of a lead drug candidate
provides invaluable insights. It directly informs
the development of control strategies for structurally
related analogs. Well, if you identify specific
impurities forming in molecule A, because of
certain reaction conditions or starting materials.
Okay. You can reasonably anticipate that similar
impurities might pop up in molecule B or C if
they undergo similar synthetic steps. Ah, so
you can be proactive. Exactly. You can implement
preventative and control measures early in the
development process for these new analogues based
on what you learn from the first molecule. It's
like learning from past experiences within that
drug family. That makes a lot of sense. Build
on previous knowledge. Precisely. And our sources
also refer to various parts of the Code of Federal
Regulations, like 21 CFR 310 .3. What's that
one? It gives the regulatory definition of a
new drug. And that definition itself implies
the extensive scrutiny applied to every aspect
of its composition, including impurities. Right.
The whole package is under review. And similarly,
21 CFR 111 .70 outlines the requirements for
setting specifications, quality standards at
various stages of manufacturing to ensure consistent
quality. Specifications for impurities, too.
Yes. And as highlighted in that ICH Q914 document,
all the detailed information gathered during
the evaluation of potential mutagenic impurities
that gets included in the regulatory application.
To justify things. To justify the choice of starting
materials and the overall impurity control strategy.
It also underscores why you need to demonstrate
that steps before your defined starting material
don't negatively impact the final impurity profile.
You've got to look back up the chain too. It
really emphasizes just how deeply regulatory
bodies delve into every single facet of drug
manufacturing and the final medicine's composition.
It's all driven by that fundamental commitment.
ensuring the safety, efficacy, and consistent
quality of the medications that reach patients.
Okay, so as we bring this deep dive to a close,
what are the key insights about impurities and
drug development that you think our listeners
should really take away? Well, I think the main
points are that impurities can pop up from a
whole array of sources during complex drug synthesis,
starting materials, reagents, intermediates,
equipment, you name it. Right, they can come
from anywhere. And highly sophisticated analytical
techniques are absolutely essential for finding
and tracking these unwanted substances, often
present in just trace amounts. The detective
work. Exactly. Crucially, various robust process
controls are put in place at each stage, controlling
reactions, purification steps to minimize their
formation and get rid of them. And all this meticulous
effort is absolutely paramount for meeting those
stringent regulatory requirements worldwide.
Precisely. A thorough understanding of the impurity
profile. especially concerning potentially harmful
stuff like genotoxins. And also, when developing
families of related drugs, it isn't just good
science. It's a requirement. It's a fundamental
regulatory requirement. And ultimately, it's
the cornerstone of ensuring the safety and effectiveness
of the medicines that you and your loved ones
rely on. This has been a truly illuminating discussion.
It really gives you a much deeper appreciation
for the incredible level of detail, the rigorous
quality control that goes into ensuring the safety
of our medications. It's a complex business.
Definitely. So here's a final thought for you,
our listener. Considering the intricate, often
delicate nature of chemical synthesis and coupling
that with the continuous advancements we're seeing
in analytical tech and process chemistry, how
might our approaches to identifying, controlling,
and maybe even preventing these tiny, often unseen
impurities evolve in the future? How can we guarantee
even safer, even more effective medicines for
everyone down the line? It's a fascinating balance,
isn't it, between innovation and that unwavering
commitment to quality assurance? Something to
think about. Thanks for joining us on the Deep
Dive.